TY - T1的进展和死亡率在轻度认知障碍男性和女性的不同吗?梅奥诊所的研究衰老(P07.155) JF -神经学乔-神经病学SP - P07.155 L首页P - P07.155六世- 78 - 1补充非盟-罗伯茨玫瑰花蕾盟盟Yonas Geda David Knopman AU -露丝Cha盟-弗农Pankratz说道盟-米歇尔Mielke Eric Tangalos AU -布拉德利Boeve盟盟-罗伯特Ivnik AU -沃尔特·罗卡AU -罗纳德·彼得森Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/P07.155.abstract N2 -目的:探讨轻度认知障碍(MCI)的结果在男性和女性。背景我们先前的研究已经证明的MCI患病率和发病率男性高于女性。设计/方法:我们研究了奥姆斯特德县的人口基数,MN居民年龄在70 - 89年10月1日,2004年。参与者评估基线和使用临床痴呆评定量表每15个月,神经系统评估,神经心理测试。诊断为MCI、痴呆或认知正常是由共识。死亡率在后续评估从死亡证明可以通过罗彻斯特流行病学项目records-linkage系统。结果:在329例MCI和普遍,282年至少有一个后续。在一个平均2.6年的随访中,发展为痴呆的速度(每1000人年)是104.6总体而言,和更高的女性(女性117.3与87.0的男性;风险比(人力资源)= 1.31,95%可信区间0.90 - -1.92)。在一个平均5.1年的随访中,死亡率(每1000人年)MCI患者罹71.1总体而言,并没有按性别差异(71.4 vs .女性,男性70.6;HR = 0.95, 95% CI 0.66 - -1.38)。 By comparison, over a median 5.2 years of follow-up, the mortality rate among 1,640 subjects who were cognitively normal at baseline was 34.9 overall, and was higher in men (41.1 vs. 28.8 in women; HR = 1.55, 95% CI 1.23-1.95).Conclusions: The faster rate of progression from MCI to dementia in women may have contributed to the higher prevalence of MCI in men observed in our cohort. Etiologic factors may account for the sex difference in incidence rates. MCI increases the risk of death equally in men and women.Supported by: U01 AG06786, P50 AG16574, K01 AG028573, K01 MH68351, R01 AG034676, Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program.Disclosure: Dr. Roberts has received research support from Abbott Laboratories. Dr. Geda has nothing to disclose. Dr. Knopman has received personal compensation for activities with Lilly Pharmaceuticals as a data safety monitoring board member. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Elan, Forest, and Baxter. Dr. Cha has nothing to disclose. Dr. Pankratz has received research support from Abbott Laboratories, Inc. Dr. Mielke has nothing to disclose. Dr. Boeve has nothing to disclose. Dr. Tangalos has received personal compensation for activities with Novartis, Amgen Inc, Eli Lilly & Company and Omnicare as a consultant and/or participant on data safety monitoring board or committees. Dr. Tangalos has received personal compensation in an editorial capacity for MD Net Guide. Dr. Tangalos holds stock and/or stock options in Johnson & Johnson. Dr. Tangalos has received research support from Baxter Pharmaceuticals. Dr. Ivnik has nothing to disclose. Dr. Rocca has nothing to disclose. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, and GE Healthcare.Thursday, April 26 2012, 14:00 pm-18:30 pm ER -